The safety issues that prompted the 2012 Stryker hip recall did not become apparent until thousands of people had been fitted with the metal hip components.
New York, New York (PRWEB) September 29, 2014
As Stryker hip lawsuits (http://www.injurybeacon.com/hip-replacement/stryker/lawsuit/) filed on behalf of individuals who were allegedly harmed by Rejuvenate and ABG II Modular-Neck Hip Stems continue to mount in U.S. courts, Bernstein Liebhard LLP notes that a new study is raising questions about the safety and effectiveness of new-generation hip replacement devices. According to Reuters, the authors of the study point out that much of the research used to bring these newer hips to market consists of engineering data, rather than data obtained via human clinical trials. This type of testing may allow problems with a new device to go undetected until it has been implanted in hundreds of patients.*
“Like the implants involved in this study, Stryker’s Rejuvenate and ABG II hip stems were brought to market without the benefit of human clinical trials. The safety issues that prompted the 2012 Stryker hip recall did not become apparent until thousands of people had been fitted with the metal hip components,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free legal evaluations to individuals who were allegedly harmed by Stryker’s Rejuvenate and ABG II Modular-Neck Hip Stems.
Stryker Hip Recall Litigation
Court records indicate that more than 3,700 product liability claims have been filed in U.S. courts since the Stryker hip recall was announced in July 2012. These include nearly 2,100 cases that are currently pending in New Jersey’s Bergen County Superior Court, where Bernstein Liebhard LLP is actively filing claims. (In Re Stryker Rejuvenate Hip Stem and the ABG II Modular Hip Stem Litigation, No. 296) Another 1,700 Rejuvenate and ABG II lawsuits have been filed in a federal multidistrict litigation now underway in U.S. District Court, District of Minnesota. (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation, No. 244)
According to court documents, all of the Stryker hip lawsuits claim that the Rejuvenate and ABG II hip stems are prone to fretting and corrosion, which can cause recipients to experience osteolysis, metallosis, premature device failure, and other painful and debilitating complications. Plaintiffs further point out that the metal hip stems were brought to market under the U.S. Food & Drug Administration’s (FDA) 510(k) clearance program, which does not require a product to undergo human clinical trials if it is shown to be substantially equivalent in design to a product already on the market.
The Stryker hip recall was announced by the U.S. Food & Drug Administration on July 6, 2012, due to a high rate of fretting and corrosion at the modular neck junction. Stryker has warned that this occurrence places recipients of the Rejuvenate and ABG II stems at risk for adverse local tissue reactions, pain and swelling. In addition, the company has recommended medical screening for all patients fitted with the components, even if they have not experienced any symptoms that would suggest a problem with their implant.**
Individuals who were allegedly affected by the Stryker hip recall for Rejuvenate and ABG II hip stems may be entitled to compensation for medical bills, lost wages, pain and suffering, or more. To learn more about filing a Stryker hip lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no-obligation case review.
*philly.com/philly/health/sportsmedicine/Are_newer_joint_replacement_really_better_than_older_options.html, Reuters (via philly.com), September 26, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP